• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载药微球经动脉化疗栓塞术联合免疫检查点抑制剂治疗晚期皮肤鳞状细胞癌:一例报告

DEB-TACE combined with ici for advanced squamous cell carcinoma of the skin: a case report.

作者信息

Wu Zhuo, Piao Xuezhe, Kang Dongxu, Jin Lan, Xu Qiang, Jin Dehao, Piao Longzhen

机构信息

Department of Oncology, Yanbian University Hospital, Yanji, Jilin, China.

Department of Intervention, Yanbian University Hospital, Yanji, Jilin, China.

出版信息

Front Oncol. 2025 Apr 22;15:1529976. doi: 10.3389/fonc.2025.1529976. eCollection 2025.

DOI:10.3389/fonc.2025.1529976
PMID:40330832
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12053265/
Abstract

We report the case of an older female patient with squamous cell carcinoma of the skin, cTXN1M0, who initially presented with a mass of approximately 4.5 cm in diameter in the left temporal region, which had a tendency to break and bleed. Given the patient's poor general status and ECOG score of grade 2, it was considered that she could not tolerate systemic chemotherapy. Therefore, we applied drug-eluting beads transarterial chemoembolization combined with immune checkpoint inhibitors to treat this patient and unexpectedly found that this regimen resulted in complete classified remission and in partial pathological response without significant adverse events.

摘要

我们报告了一例老年女性皮肤鳞状细胞癌患者,cTXN1M0,最初表现为左颞部一个直径约4.5厘米的肿块,有破溃出血倾向。鉴于患者一般状况较差且东部肿瘤协作组(ECOG)评分为2级,认为她无法耐受全身化疗。因此,我们应用载药微球经动脉化疗栓塞联合免疫检查点抑制剂治疗该患者,意外发现该方案导致完全分类缓解和部分病理缓解,且无明显不良事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/c3cb5ba71b59/fonc-15-1529976-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/ed2a19baf120/fonc-15-1529976-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/8a6414b94157/fonc-15-1529976-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/4cb732b6dc30/fonc-15-1529976-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/c3cb5ba71b59/fonc-15-1529976-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/ed2a19baf120/fonc-15-1529976-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/8a6414b94157/fonc-15-1529976-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/4cb732b6dc30/fonc-15-1529976-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7802/12053265/c3cb5ba71b59/fonc-15-1529976-g004.jpg

相似文献

1
DEB-TACE combined with ici for advanced squamous cell carcinoma of the skin: a case report.载药微球经动脉化疗栓塞术联合免疫检查点抑制剂治疗晚期皮肤鳞状细胞癌:一例报告
Front Oncol. 2025 Apr 22;15:1529976. doi: 10.3389/fonc.2025.1529976. eCollection 2025.
2
Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.药物洗脱微球经动脉化疗栓塞联合免疫检查点抑制剂治疗肝细胞癌的安全性评价:治疗间隔小于 1 个月时肝脓肿风险增加。
Eur J Radiol. 2024 Jan;170:111266. doi: 10.1016/j.ejrad.2023.111266. Epub 2023 Dec 15.
3
Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching.载药微球经动脉化疗栓塞联合全身化疗及免疫检查点抑制剂治疗不可切除肝内胆管癌的疗效分析:一项基于倾向评分匹配的多中心回顾性队列研究
World J Surg Oncol. 2025 Jan 24;23(1):21. doi: 10.1186/s12957-025-03679-4.
4
Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.载药微球动脉化疗栓塞联合全身化疗及靶向治疗在结直肠癌肝转移中的疗效。
World J Surg Oncol. 2023 Dec 1;21(1):378. doi: 10.1186/s12957-023-03253-w.
5
Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study.碘油联合载药微球与单纯载药微球用于肝细胞癌经动脉化疗栓塞术的多中心研究
Acad Radiol. 2024 Dec;31(12):4912-4922. doi: 10.1016/j.acra.2024.05.033. Epub 2024 Jun 12.
6
Clinical evaluation of oxaliplatin-loaded drug-eluting callispheres beads transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.载奥沙利铂药物洗脱微球经导管动脉化疗栓塞治疗不可切除或复发性食管癌的临床评价。
World J Surg Oncol. 2024 Oct 10;22(1):272. doi: 10.1186/s12957-024-03546-8.
7
5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis.5-氟尿嘧啶联合 CalliSphere 载药微球与常规经动脉化疗栓塞治疗不可切除肝细胞癌:倾向评分加权分析。
Sci Rep. 2024 Oct 26;14(1):25588. doi: 10.1038/s41598-024-77531-2.
8
Efficacy and safety of raltitrexed-eluting CalliSpheres bead transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma: a single-arm, prospective study.雷替曲塞洗脱载药微球经动脉化疗栓塞术治疗中期肝细胞癌患者的疗效与安全性:一项单臂前瞻性研究
Ther Adv Med Oncol. 2024 Feb 14;16:17588359241229661. doi: 10.1177/17588359241229661. eCollection 2024.
9
The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.载奥沙利铂药物洗脱微球经动脉化疗栓塞术治疗不可切除或晚期肺癌的安全性和有效性
Front Pharmacol. 2022 Nov 28;13:1079707. doi: 10.3389/fphar.2022.1079707. eCollection 2022.
10
Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.在实际临床环境中肝细胞癌的碘油灌注与载药微球经动脉化疗栓塞术的比较
Scand J Gastroenterol. 2019 Jul;54(7):905-912. doi: 10.1080/00365521.2019.1632925. Epub 2019 Jul 9.

本文引用的文献

1
Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.皮肤鳞状细胞癌的分子靶向治疗:最新进展与临床意义
EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024.
2
Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer: A case series study.载吉西他滨的Callispheres药物洗脱微球治疗晚期不可切除肺癌患者的临床疗效:一项病例系列研究。
Front Pharmacol. 2022 Sep 29;13:992526. doi: 10.3389/fphar.2022.992526. eCollection 2022.
3
The efficacy and safety of I brachytherapy combined with pre-operative transarterial chemoembolization in patients with locally advanced head and neck cancer.
I粒子近距离放射治疗联合术前经动脉化疗栓塞术治疗局部晚期头颈癌的疗效与安全性
Front Oncol. 2022 Sep 14;12:992399. doi: 10.3389/fonc.2022.992399. eCollection 2022.
4
Drug-Eluting Embolics Chemoembolization for the Management of Recurrent or Advanced Head and Neck Cancer.药物洗脱微球栓塞化疗治疗复发性或晚期头颈部癌症。
J Vasc Interv Radiol. 2022 Aug;33(8):949-955. doi: 10.1016/j.jvir.2022.05.002. Epub 2022 May 13.
5
The risk of metastases from squamous cell carcinoma of the skin.皮肤鳞状细胞癌发生转移的风险。
Int J Dermatol. 2023 Apr;62(4):483-486. doi: 10.1111/ijd.16164. Epub 2022 Mar 24.
6
Transarterial Embolization for Bleeding in Patients with Head and Neck Cancer: Who Benefits?经动脉栓塞治疗头颈部癌症出血:哪些患者获益?
Laryngoscope. 2021 Nov;131(11):E2777-E2783. doi: 10.1002/lary.29611. Epub 2021 May 7.
7
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.替雷利珠单抗联合化疗与单纯化疗一线治疗晚期鳞状非小细胞肺癌的随机 3 期临床试验。
JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366.
8
Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.皮肤鳞状细胞癌:从病理生理学到新型治疗方法
Biomedicines. 2021 Feb 9;9(2):171. doi: 10.3390/biomedicines9020171.
9
Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma.黑色素瘤和皮肤鳞状细胞癌的靶向治疗与传统化疗
Facial Plast Surg. 2020 Apr;36(2):186-193. doi: 10.1055/s-0040-1709126. Epub 2020 May 15.
10
Update of the Management of Cutaneous Squamous-cell Carcinoma.皮肤鳞状细胞癌的治疗进展。
Acta Derm Venereol. 2020 Jun 3;100(11):adv00143. doi: 10.2340/00015555-3498.